IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma

Matthew N. Svalina, Ken Kikuchi, Jinu Abraham, Sangeet Lal, Monika A. Davare, Teagan P. Settelmeyer, Michael C. Young, Jennifer L. Peckham, Yoon Jae Cho, Joel E. Michalek, Brian S. Hernandez, Noah E. Berlow, Melanie Jackson, Daniel J. Guillaume, Nathan R. Selden, Darell D. Bigner, Kellie J. Nazemi, Sarah C. Green, Christopher L. Corless, Sakir GultekinAtiya Mansoor, Brian P. Rubin, Randall Woltjer, Charles Keller

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Through the comparison of cytokines and growth factors in the cerebrospinal fluid (CSF) of metastatic medulloblastoma patients with factors also in conditioned media of metastatic MYC amplified medulloblastoma or leptomeningeal cells, we were led to explore the bioactivity of IGF1 in medulloblastoma by elevated CSF levels of IGF1, IGF-sequestering IGFBP3, IGFBP3-cleaving proteases (MMP and tPA), and protease modulators (TIMP1 and PAI-1). IGF1 led not only to receptor phosphorylation but also accelerated migration/adhesion in MYC amplified medulloblastoma cells in the context of appropriate matrix or meningothelial cells. Clinical correlation suggests a peri-/sub-meningothelial source of IGF-liberating proteases that could facilitate leptomeningeal metastasis. In parallel, studies of key factors responsible for cell autonomous growth in MYC amplified medulloblastoma prioritized IGF1R inhibitors. Together, our studies identify IGF1R as a high value target for clinical trials in high risk medulloblastoma.

Original languageEnglish (US)
Article number27012
JournalScientific Reports
StatePublished - Jun 3 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma'. Together they form a unique fingerprint.

Cite this